polioviru
pv
small
nonenvelop
viru
positivesens
singlestrand
rna
genom
nt
belong
genu
enteroviru
famili
picornavirida
fecoor
infect
pv
invad
central
nervou
system
primarili
via
viremia
show
posit
correl
pv
paralyt
destroy
motor
neuron
caus
immun
live
oral
pv
vaccin
opv
inactiv
pv
vaccin
ipv
induc
product
antipv
antibodi
serum
prevent
pv
central
nervou
system
invas
poliomyel
serosurveil
perform
monitor
antipv
neutral
antibodi
titr
serum
potenti
suscept
popul
evalu
countri
potenti
vulner
poliomyel
outbreak
convent
pv
neutral
test
cpnt
use
cell
cultur
infecti
pv
strain
usual
attenu
vaccin
strain
current
perform
measur
antipv
neutral
serosurveil
japan
perform
prefectur
laboratori
everi
year
sinc
individu
prefectur
wide
age
rang
age
year
monitor
serosurveil
also
import
japan
introduct
sabin
strainbas
ipv
sipv
sipv
induc
similar
persist
antipv
antibodi
convent
wildtypestainbas
ipv
use
booster
adult
histori
opv
recent
report
suggest
rapid
declin
antibodi
titr
sipv
persist
antipv
antibodi
children
vaccin
sipv
without
opv
remain
poorli
understood
endgam
polio
erad
high
level
pv
biosecur
import
ever
third
edit
global
action
plan
minim
polioviru
facilityassoci
risk
typespecif
erad
wild
poliovirus
sequenti
cessat
oral
polio
vaccin
use
gap
iii
adopt
may
indigen
wild
type
pv
declar
erad
gapiii
rais
biosafeti
level
type
pv
strain
annex
gap
iii
correspond
plu
addit
condit
restrict
use
type
strain
biolog
test
laboratori
convent
biosecur
level
one
major
challeng
implement
gap
iii
sustain
serosurveil
system
restrict
use
infecti
pv
strain
implement
cpnt
could
perform
laboratori
convent
biosecur
level
previous
produc
virusfre
pv
pseudoviru
pvpv
could
serv
altern
infecti
pv
pvpv
possess
luciferaseencod
pv
replicon
capsid
show
singl
cycl
infect
suscept
cell
adsorptionuncoatingrepl
without
produc
infecti
viru
pvpv
use
quantit
analys
antivir
antityp
pv
neutral
activ
stool
context
neutral
test
pseudotyp
virus
develop
virus
control
high
biosecur
level
eg
ebola
viru
sarscov
lyssavirus
nipah
viru
highli
pathogen
avian
influenza
virus
previou
studi
develop
pseudoviru
pv
neutral
test
ppnt
use
pvpv
capsid
wildtyp
follow
report
group
also
found
good
correl
ppnt
ppnt
larg
character
three
factor
capsid
protein
type
eg
capsid
protein
wildtyp
strain
vaccin
strain
titr
amount
pvpv
threshold
valu
pvpv
infect
determin
neutral
antibodi
titr
capsid
protein
type
critic
type
pv
exemplifi
signific
antigen
differ
type
sabin
strain
parent
mahoney
strain
emerg
type
wildtyp
strain
significantli
low
absolut
titr
infecti
unit
pvpv
could
determin
use
focu
luciferas
signal
pvpvinfect
cell
might
use
determin
rel
cpnt
neutral
titr
determin
endpoint
read
cytopath
effect
infect
cell
allornon
read
ppnt
neutral
titr
determin
read
pvpv
infect
repres
percentag
luciferas
signal
infect
cell
allornon
read
therefor
threshold
valu
requir
ppnt
defin
appar
neutral
pvpv
threshold
valu
pvpv
infect
induct
estim
give
best
fit
cpnt
result
pvpv
infect
variat
report
threshold
valu
might
suggest
robust
ppnt
seroposit
rate
determin
wide
rang
threshold
valu
substanti
unaffect
eg
seroposit
rate
type
determin
rang
threshold
valu
rational
determin
threshold
valu
remain
provid
analys
antigen
pvpv
capsid
protein
wildtyp
strain
pvpv
wt
sabin
strain
pvpv
sabin
set
human
sera
obtain
healthi
volunt
age
total
sampl
addit
provid
rational
threshold
valu
ppnt
base
distribut
pvpv
infect
cpnt
titr
previou
studi
produc
type
pvpv
possess
luciferaseencod
pv
replicon
base
mahoney
strain
capsid
wildtyp
strain
type
mahoney
type
type
saukett
pv
wt
pv
wt
wt
respect
construct
pv
capsid
express
vector
express
capsid
protein
type
sabin
strain
also
produc
type
pvpv
possess
luciferaseencod
pv
replicon
base
mahoney
strain
capsid
type
sabin
strain
respect
pv
sabin
pv
sabin
sabin
respect
fig
obtain
type
pvpv
sabin
high
titr
iu
iu
per
ml
respect
lower
pvpv
wt
next
optim
amount
pvpv
sabin
ppnt
standard
antisera
fig
specif
similar
neutral
profil
observ
pvpv
sabin
rang
examin
amount
iu
use
iu
pvpv
sabin
ppnt
previous
perform
ppnt
pvpv
wt
human
serum
determin
threshold
valu
maxim
fit
seroposit
rate
popul
neutral
titr
least
howev
could
directli
compar
result
cpnt
perform
sabin
strain
analys
direct
correl
cpnt
ppnt
analys
distribut
pvpv
infect
presenc
human
serum
dilut
cpnt
titr
fig
pvpv
sabin
infect
show
sharp
peak
around
median
type
pvpv
sabin
respect
percentag
serum
sampl
show
less
pvpv
infect
cpnt
titr
type
pvpv
sabin
respect
percentag
serum
sampl
show
less
pvpv
infect
cpnt
titr
type
pvpv
sabin
respect
broader
peak
width
type
type
might
reflect
intrins
weak
antigen
type
pv
human
vaccin
opv
fig
profil
curv
type
pvpv
wt
like
type
pvpv
sabin
contrast
curv
wt
significantli
differ
sabin
show
broad
peak
width
median
result
indic
substanti
suppress
pvpv
infect
presenc
human
serum
dilut
cpnt
titr
signific
antigen
differ
type
pvpv
next
threshold
valu
pvpv
sabin
analys
use
seroposit
rate
degre
correl
compar
cpnt
fig
type
pvpv
sabin
seroposit
rate
almost
equal
rang
examin
threshold
valu
threshold
valu
within
variat
cpnt
sabin
show
rel
low
seroposit
rate
threshold
valu
fig
highest
degre
correl
cpnt
ppnt
term
residu
sum
squar
observ
threshold
valu
suggest
threshold
valu
might
optim
ppnt
type
pvpv
sabin
sabin
threshold
valu
seem
give
optim
correl
suggest
level
pvpv
infect
distribut
includ
around
peak
serv
optim
threshold
ppnt
fig
threshold
valu
type
pvpv
sabin
sabin
ppnt
pvpv
sabin
show
high
correl
cpnt
respect
type
result
pvpv
sabin
like
pvpv
wt
respect
type
correl
degre
drastic
improv
pvpv
sabin
compar
pvpv
wt
vs
correl
cpnt
ppnt
consist
observ
among
differ
age
group
pvpv
sabin
contrast
pvpv
wt
fig
type
pvpv
sabin
correl
also
observ
among
age
group
previous
observ
pvpv
wt
one
critic
point
pv
serosurveil
estim
seroposit
rate
accur
determin
overal
agespecif
seroposit
rate
ppnt
support
potenti
ppnt
altern
cpnt
along
observ
high
correl
analys
reproduc
ppnt
fig
first
test
reproduc
ppnt
pvpv
sabin
use
standard
monkey
antipv
sera
u
per
twenti
independ
experi
median
valu
pvpv
sabin
infect
cpnt
titr
standard
antisera
appear
like
threshold
valu
determin
type
median
type
pvpv
sabin
respect
experi
ppnt
titr
standard
sera
determin
fig
also
analys
lottolot
differ
pvpv
sabin
standard
monkey
antipv
sera
fig
two
differ
lot
pvpv
sabin
show
similar
neutral
curv
antisera
next
test
reproduc
set
human
sera
total
sampl
three
independ
experi
fig
supplementari
data
found
consist
seroposit
rate
distribut
neutral
titr
among
experi
result
suggest
high
reproduc
ppnt
robust
establish
condit
summari
clarifi
antigen
differ
type
pv
strain
use
ppnt
provid
rational
determin
threshold
valu
ppnt
high
reproduc
safeti
without
use
infecti
virus
ppnt
pvpv
sabin
could
serv
altern
cpnt
serosurveil
endgam
polio
erad
program
fig
rd
cell
human
rhabdomyosarcoma
cell
cell
human
embryon
kidney
cell
cultur
monolay
dulbecco
modifi
eagl
medium
dmem
supplement
foetal
calf
serum
fc
vero
cell
african
green
monkey
kidney
cell
cultur
monolay
eagl
minimum
essenti
medium
emem
supplement
bovin
serum
albumin
bsa
fraction
v
sigma
rd
cell
use
pv
ppnt
titrat
vero
cell
use
cpnt
cell
use
produc
pvpv
type
pvpv
wt
possess
luciferaseencod
pv
replicon
base
mahoney
strain
capsid
protein
deriv
mahoney
saukett
human
sera
collect
healthi
volunt
age
inform
consent
parent
legal
guardian
minor
experi
perform
approv
committe
ethic
regul
nation
institut
infecti
diseas
japan
experi
perform
accord
relev
guidelin
regul
escherichia
coli
strain
stratagen
use
prepar
plasmid
ligat
dna
fragment
perform
use
infus
hd
clone
kit
clontech
pcr
perform
use
kod
plu
dna
polymeras
toyobo
revers
transcriptionpcr
rtpcr
perform
use
revertra
plu
kit
toyobo
dna
sequenc
perform
use
bigdy
termin
cycl
sequenc
readi
reaction
kit
appli
biosystem
analys
genet
analys
appli
biosystem
construct
express
vector
capsid
protein
type
sabin
strain
genbank
respect
enhanc
green
fluoresc
protein
egfp
gene
fuse
capsidproteincod
region
type
sabin
strain
use
pcr
insert
ultra
express
vector
takara
digest
smai
sali
egfp
code
region
amplifi
use
pcr
clontech
templat
follow
primer
set
code
region
egfp
linker
primer
underlin
pv
capsidproteincod
region
amplifi
use
rtpcr
viral
genom
rna
templat
follow
primer
set
code
region
capsid
protein
primer
underlin
type
sabin
type
sabin
type
sabin
pvpv
prepar
previous
report
briefli
sixwel
plate
falcon
confluent
monolay
cell
transfect
correspond
pv
capsidexpress
vector
per
well
use
lipofectamin
reagent
invitrogen
cell
incub
ml
dmem
supplement
fc
per
well
h
rna
transcript
pv
replicon
obtain
use
ribomax
largescal
rna
product
system
kit
promega
drailinear
dna
ppvfluc
mc
encod
pv
replicon
base
mahoney
firefli
luciferas
gene
instead
capsidcod
region
templat
rna
transcript
transfect
monolay
cell
transient
express
pv
capsid
protein
h
posttransfect
use
lipofectamin
messengermax
reagent
invitrogen
cell
harvest
h
posttransfect
rna
transcript
cell
show
cpe
cell
store
infecti
unit
pvpv
stock
solut
determin
count
number
cell
infect
pvpv
h
postinfect
pi
stain
use
protein
indirect
immunofluoresc
describ
cpnt
perform
accord
standard
procedur
recommend
describ
briefli
dilut
seri
human
sera
prepar
emem
supplement
bsa
result
dilut
dilut
sera
emem
supplement
bsa
ad
three
plate
type
sabin
strain
cell
cultur
infect
dose
ad
well
plate
one
plate
serotyp
pv
total
plate
incub
h
incub
vero
cell
suspens
emem
supplement
bsa
cell
ad
well
plate
plate
incub
day
neutral
antibodi
titr
serum
determin
endpoint
serum
determin
presenc
absenc
cpe
cell
ppnt
perform
report
previous
human
sera
sampl
standard
antipv
sera
u
per
posit
control
dilut
dmem
supplement
fc
dilut
dilut
seri
made
result
dilut
dilut
sera
dmem
supplement
fc
mock
treatment
ad
three
plate
greiner
bioon
next
type
pvpv
solut
iu
ad
well
plate
one
plate
serotyp
pvpv
total
plate
plate
centrifug
g
sec
platespin
kubota
centrifug
plate
incub
overnight
incub
rd
cell
suspens
dmem
supplement
fc
cell
ad
well
plate
plate
incub
h
luciferas
signal
infect
cell
measur
h
pi
steadyglo
luciferas
assay
system
promega
use
arvo
x
luminomet
perkinelm
accord
manufactur
instruct
pvpv
infect
calcul
percentag
luciferas
signal
infect
cell
luciferas
signal
mocktreat
cell
taken
neutral
antibodi
titr
determin
reciproc
number
highest
dilut
serum
suppress
pvpv
infect
less
